文献速递青光眼

MINIject引流系统治疗未控制青光眼的STAR-I首次人体试验两年结果

Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial.
PubMed 文献 · Br J Ophthalmol · 2020-10-03

STAR-I首次人体单臂研究评估MINIject睫状体上腔微创引流装置单独植入治疗药物未控制的开角型青光眼,25例植入,21例随访至2年。2年时平均眼压从基线23.2±2.9 mmHg降至13.8±3.5 mmHg(降幅40.7%),用药从2.0±1.1种降至1.0±1.3种,完全成功率47.6%,部分成功率100%,无严重眼部不良事件。

要点

  • 2年眼压降幅40.7%,平均眼压降至13.8±3.5 mmHg。
  • 完全成功率47.6%(10/21),部分成功率100%(21/21)。
  • 无严重眼部不良事件或额外青光眼手术,中央内皮细胞密度轻度下降5%。

核心结论

  • MINIject睫状体上腔引流系统单独植入在24个月内显示有前景的降眼压和减少用药效果,不良事件少。

研究设计与样本

  • 前瞻性、多中心、首次人体、单臂干预研究,评估25例药物未控制开角型青光眼患者单独行ab interno植入5 mm长葡萄膜巩膜装置(STAR生物相容材料),21例随访至2年。

主要发现

  • 平均基线眼压23.2±2.9 mmHg,使用2.0±1.1种降眼压药物成分。
  • 植入2年后平均眼压降至13.8±3.5 mmHg(降幅40.7%),使用1.0±1.3种药物。
  • 2年随访时完全成功率47.6%(10/21),部分成功率100%(21/21)。
  • 全部患者达到20%眼压降幅,48%患者无需用药。
  • 无严重眼部不良事件或额外青光眼手术;中央内皮细胞密度从2411 cells/mm2(n=26)轻度降至2341 cells/mm2(n=21),匹配眼降幅5%,无患者降幅≥30%。

关键数值与推荐

  • 完全成功定义为昼夜眼压≤21 mmHg且>5 mmHg、眼压降幅20%且无需青光眼药物;部分成功定义为达到上述眼压标准伴或不伴用药。

临床怎么用

  • 对于药物未控制的开角型青光眼,MINIject单独植入可作为微创降眼压选项,2年数据显示降眼压和减少用药效果且安全性较好。

局限性

  • 首次人体单臂研究,样本量小(25例植入,21例随访至2年),缺乏对照,结论需更大规模对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: The current study evaluates the efficacy and safety of the stand-alone implantation of the MINIject (iSTAR Medical, Wavre, Belgium) supraciliary, microinvasive glaucoma drainage device in patients with medically uncontrolled open-angle glaucoma. METHODS: This prospective, multicentre, first-in-human, single-arm interventional study evaluated stand-alone, ab interno implantation in 25 patients of a 5 mm long uveoscleral device made of STAR biocompatible material, which is a soft, microporous, flexible silicone. The primary outcome was the reduction of intraocular pressure (IOP) at 6 months compared with baseline, and follow-up continued until 2 years for 21 patients. Secondary outcomes included success defined as diurnal IOP of ≤21 mmHg and >5 mmHg with an IOP reduction of 20% without (complete) or with/without (qualified) glaucoma medication. RESULTS: Mean baseline IOP was 23.2±2.9 mmHg on 2.0±1.1 glaucoma medication ingredients and decreased to 13.8±3.5 mmHg (-40.7% reduction) on 1.0±1.3 medications 2 years after implantation. Complete success was achieved in 47.6% of patients (10/21) and qualified success in 100% of patients (21/21) at the 2-year follow-up. All patients achieved a 20% IOP reduction with 48% of patients medication-free. No serious ocular adverse events or additional glaucoma surgery were reported. Mean central endothelial cell density (ECD) mildly decreased from 2411 cells/mm2 (n=26) to 2341 cells/mm2 (n=21) at 24 months, which represents a 5% decrease for matched eyes. No patient had a ≥30% decrease in central ECD. CONCLUSION: This first-in-human study on the stand-alone implantation of the MINIject supraciliary drainage system shows promising IOP-lowering results and medication reduction over 24 months with few adverse events. TRIAL REGISTRATION NUMBER: NCT03193736.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Denis P, Hirneiß C, Durr GM, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol. 2020. PMID: 33011690. doi:10.1136/bjophthalmol-2020-316888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。